ABUS Shares Outstanding History

Below is a table of the ABUS shares outstanding history going back to 11/15/2010:

Date	ABUS Shares Outstanding
11/15/2010	10.34M
12/31/2010	10.34M
2/28/2011	10.34M
10/31/2011	12.15M
12/31/2011	12.15M
5/31/2012	14.00M
12/31/2012	14.31M
1/3/2013	14.30M
9/30/2013	14.55M
2/28/2014	19.69M
3/21/2014	21.95M
5/8/2014	22.08M
8/12/2014	22.11M
10/30/2014	22.31M
3/9/2015	46.57M
4/30/2015	54.22M
7/31/2015	54.33M
10/31/2015	54.57M
2/29/2016	54.63M
4/30/2016	54.63M
7/31/2016	54.80M
10/31/2016	54.84M
3/14/2017	55.02M
4/30/2017	55.02M
7/31/2017	55.03M
10/31/2017	55.05M
3/6/2018	77.66M
4/30/2018	78.84M
7/31/2018	55.40M
10/31/2018	55.48M
3/5/2019	56.12M
4/30/2019	56.85M
7/31/2019	56.85M
10/31/2019	56.85M
3/2/2020	68.94M
8/5/2020	80.91M
11/5/2020	84.91M
3/3/2021	95.58M
5/3/2021	96.39M
8/3/2021	99.16M
11/2/2021	135.27M
3/3/2022	148.64M
5/3/2022	148.73M
8/2/2022	149.95M
11/8/2022	156.47M
2/28/2023	162.57M
5/2/2023	166.13M
8/1/2023	167.56M
3/1/2024	179.49M

Also see: ABUS Market Cap History
ABUS YTD Return

ABUS Historical Shares Outstanding:
+23.94% CAGR

Mouse over chart for data details

11/15/2010

...

3/1/2024

Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer. We show 49 historical shares outstanding datapoints in our coverage of ABUS's shares outstanding history.

Understanding the changing numbers of ABUS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ABUS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ABUS by allowing them to research ABUS shares outstanding history as well as any other stock in our coverage universe.

Quotes delayed 20 minutes

Free ABUS Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

10 ETFs With Stocks That Insiders Are Buying

10 ETFs With Most Upside To Analyst Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Energy Stocks You Can Buy Cheaper Than Insiders Did

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active Call & Put Options of the S&P 500 Components

Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Join SharesOutstandingHistory.com
Create a FREE account to continue
Already have an account? LOG IN

Full Disclaimer & Terms of Use and Privacy Policy. Important: If you are in Canada or the European Union, you must click here for alternate registration page.

✓

Immediate access to our ABUS Shares Outstanding History page as well as our full coverage universe of stocks

✓

Complimentary report on monthly dividend paying stocks

✓

Daily market updates from our Contrarian Outlook team

✓

Join FREE with just your email address

Welcome back!

SharesOutstandingHistory.com and parent company BNK Invest, Inc. value our relationship with you and would like to continue providing accurate and tailored communications to fit your investing needs. To receive our publications and other relevant communications, Canada's anti-spam legislation (''CASL'') and the European Union's General Data Protection Regulation (''GPDR'') requires us to obtain your express consent. Please provide your consent to continue. In any email we send, you will be given the option to withdraw your consent or unsubscribe from any or all of our newsletters or publications at any time.

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.

ABUS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved